David Ilson

David Ilson at Memorial Sloan Kettering is a leader in esophageal and gastroesophageal junction cancer whose contributions span chemoradiation, perioperative therapy, and systemic treatment for advanced disease. His research has contributed to the ramucirumab story and the evaluation of novel targeted agents in GEJ adenocarcinoma. He has been a key contributor to NCCN guidelines for esophageal and gastric cancer and has participated in multiple pivotal trials including KEYNOTE-811 for HER2-positive gastric cancer. His expertise in multimodality treatment approaches for esophageal cancer is widely recognized.